On the evening of January 9, 2020, TargetRx's 2019 Annual Grand Ceremony kicked off in a harmonious and festive atmosphere. Guests, company leaders and employees gathered together for a good night. On the occasion of the arrival of the New Year, TargetRx would like to extend its sincere New Year greetings and heartfelt wishes to everyone!

TargetRx Milestones in 2019

Dr. Yihan Wang made the 2019 annual summary

Dr. Yihan Wang, Chairman and General Manager of TargetRx, counted TargetRx’s fruitful achievements in the project R&D, patent application, financing and honors in 2019, commended TargetRx’s teams for their hard work, and described TargetRx’s plans and prospects for 2020.

▲ Dr. Yihan Wang made the 2019 annual summary and the 2020 work arrangement

2019 witnessed TargetRx's milestone breakthroughs in ongoing research projects. The pre-clinical safety evaluation experiments of the two leading products were progressing smoothly — the preliminary application materials for the new drug TGRX-678 for treating CML was submitted, and the application materials for the lung cancer ALK inhibitor TGRX-326 will be submitted this year (2020); a number of patent applications from TargetRx’s other R&D production lines was also submitted, some of which authorized. Up to now, TargetRx has applied for more than 100 patents and obtained 18 authorizations, showing TargetRx's strong innovation and R&D capabilities.

In 2019, TargetRx also received much recognition from the biotech industry and all walks of life. In September, TargetRx won the title of Top 20 Leading Biotechnology Companies in Shenzhen 2019 - Pioneer Enterprise; in October, TargetRx listed as the Emerging Enterprise in the second Top 50 Innovative Biotechnology Companies in Guangdong-Hong Kong-Macao Greater Bay Area Award. TargetRx strived to be a leading innovative drug R&D company in the Guangdong-Hong Kong-Macao Greater Bay Area, and these awards are a full recognition of the efforts of TargetRx in the field of new drug R&D in the five years since its establishment.

In 2020, TargetRx will continue to overcome difficulties in the R&D of new anti-cancer drugs, and carry out cooperation with various pharmaceutical companies, government parks, universities and research institutes to enhance its scientific R&D capabilities, accelerate the commercialization of scientific research achievements, thus promoting the development of industrial economy.

TargetRx's existing achievements are inseparable from the support and help of TargetRx's directors and leaders, investors and the Shenzhen Government. We are grateful to them. In 2020, TargetRx staff, with full confidence and determination and under the leadership of Dr. Wand Yihan, will work together to face challenges, overcome obstacles, and move forward steadily.

Speakers at the annual meeting

The invited guests spoke highly of TargetRx's work results in 2019 and encouraged TargetRx to stay true to its original aspiration and continue to make breakthroughs in the new year.

Guanping Feng

Founder of China's graphene industry, Founding Dean of Research Institute of Tsinghua University in Shenzhen, Chairman of Leaguer Stock Co., Ltd., and one of the angel investors of TargetRx

“I believe that the combination of graphene and TargetRx’s targeted drugs may cure cancer and other diseases that are harmful to human health, blaze a new path of cancer treatment, and make certain contributions in the field of biomedicine.”

Speakers of employee representatives

The positive and rigorous working attitude of TargetRx's employees has helped the rapid growth of TargetRx within five years. Three employees from the R&D Department spoke as employee representatives, summarizing and reporting their work results, gains and insights obtained in 2019.

Dr. Liu, Head of Pre-Clinical Study

“In TargetRx, I understand how a drug that can really save people goes from the laboratory to the patient's hands step by step. Now our self-developed drugs are entering the clinic stage, I feel very happy and honored. Thanks to TargetRx's leaders and investors for providing a platform that allows us to grow together with TargetRx.”

Dr. Shi, Director of Biological R&D

“We have gradually improved the function of biological laboratories and expanded the scope of research to quickly advance various projects by providing accurate and reliable biological study data. In the new year, the biological team will seek further expansion.”

Engineer Xing, Senior Researcher of Synthesis, Leader of Chemical Synthesis Team

“This is not just a job; it is a great cause. There is nothing nobler and greater than benefiting the human health. Although the laboratory R&D is boring and difficult, only by always keeping in mind our mission and strengthening our convictions can we be able to achieve our ideals and live up to our years.”

Games in the party

A party was organized after the meeting. During the party, TargetRx staff played funny games together. The team games promoted the communication between employees and enhanced the friendship between new and old colleagues.

TargetRx made rapid progress in research and development in 2019. We sincerely thank TargetRx's shareholders, investors, government and all sectors of society for their eager attention and support. Look up at the stars and keep your feet on the ground. Time is fleeting. TargetRx will embark on a new journey. Under the leadership of Dr. Yihan Wang and TargetRx’s board of directors, we will continue to be unswerving, pragmatic, pioneering, and innovative.

We look forward to working with and welcome more new talents with common vision and ambitions to contribute to the development of Chinese local new drugs for cancer together.